Frontiers in Pediatrics | www.frontiersin.org
1 April 2019 | Volume 7 | Article 159
Report the Abuse fact sheet
AIDS Research and Therapy 2015, 12:12 (24 April 2015)
This 2015 edition not only updates important changes published in the MEC fifth edition, but also includes several user-friendly features and additional supplemental information, in response to requests WHO has received from stakeholders and partners.
20 Mart 2020
http://www.covid19-druginteractions.org
Çeviren:
Kamu Hastaneleri Genel Müdürlüğü
Tedarik Planlama, Stok ve Lojistik Yönetimi Daire Başkanlığı Hastane Eczacılığı Yönetim Birimi
The Africa Centres for Disease Control and Prevention (Africa CDC) is concerned about inaccurate information being distributed through traditional and social media regarding prevention and treatment of novel coronavirus disease (COVID-19).
CDC Afrique est préoccupé par les informations inexactes distribués par les médias traditionnels et sociaux en ce qui concerne la prévention et le traitement des maladies nouvelles coronavirus (Covid-19).
Sur la base d’un examen des preuves et de l’évaluation d’experts, le CDC Afrique r...ecommande
more
As of 31 October 2020 This is the tenth edition of this summary of rapid systematic reviews, which includes the results of a rapid systematic review of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. I...n this review, 46 therapeutic options are examined. The Pan American Health Organization (PAHO) is continually monitoring ongoing research on any possible therapeutic options. As evidence emerges, then PAHO will immediately assess and update its position, and particularly as it applies to any special sub-group populations such as children, expectant mothers, those with immune conditions, etc.
more
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi...th severe or critical COVID-19, and modifies previous recommendations for the neutralizing monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe COVID-19.
more
Результаты исследования «Изучение распространенности коронавирусной инфекции COVID-19 среди инфицированных ВИЧ пациентов вРоссии ивлияния эпидемии коронавирусной... инфекции COVID-19 на оказание медицинской помощипри ВИЧ-инфекции»
This study shows the negative impact that the COVID-19 pandemic is having on access to HIV care in the Russian Federation and shows that people living with HIV in the country are more susceptible to COVID-19 but less likely to seek testing or treatment.
More than a third of people living with HIV who were surveyed reported some impact on HIV services, including about 4% who reported that they had missed taking antiretroviral therapy because they could not get the medicine and nearly 9% who reported that they had missed taking medicine for tuberculosis prevention. However, the majority of respondents (about 70% of people living with HIV) did not experience problems obtaining antiretroviral therapy and about 22% reported that antiretroviral medicines were delivered to their home. More than 900 respondents from 68 regions of the Russian Federation, including people living with HIV and those who are not, were reached by the study.
more
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
Guía de tratamiento farmacológico y manejo deescenarios clínicos de casos de COVID-19 – enero 2022 Guía de tratamiento farmacológico y manejo deLeer más
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.